Study of cladribine+venetoclax after failure of venetoclax+hypomethylating agent in monocytic AML
Primary Objective
To assess the efficacy of cladribine+venetoclax (Clad/Ven) in AML with a monocytic phenotype that is relapsed after or refractory to HMA/Ven
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Christine Mcmahon, MD
Study ID
Protocol Number: 23-0273
More information available at ClinicalTrials.gov: NCT06232655
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers